Cardiovascular system ↗ApoB particles circulate
VLDL remnants, IDL, LDL, and Lp(a) carry cholesterol through plasma. Concentration multiplied by exposure time shapes arterial opportunity.
CARDIOVASCULAR / ATHEROSCLEROSIS
From one retained particle
to an arterial event.
Atherosclerosis is a cumulative artery-wall process. This page separates ApoB entry and retention, particle modification, immune response, plaque structure, disruption, coagulation, and the distinct heart and brain consequences.
14-STAGE DEEP DIVE
Cumulative biology,
then an acute branch.
Stages 1–12 usually evolve over years. Stages 13–14 can occur over minutes. Presence of plaque does not mean disruption is inevitable, and no single food or glucose excursion creates an acute plaque.
Endothelial crossing
Particles enter susceptible arterial regions, especially where flow patterns and endothelial biology favor entry.
Proteoglycan binding
ApoB interactions with extracellular matrix retain particles in the intima—the response-to-retention initiating step.
Particle modification
Retained particles may oxidize, aggregate, undergo enzymatic change, or become glycated, altering inflammatory and uptake signals.
Endothelial activation
Adhesion molecules and chemokines recruit circulating monocytes toward the retained-particle signal.
Monocyte entry
Monocytes cross into the intima and differentiate into macrophages within the developing lesion.
Scavenger uptake
Macrophage scavenger receptors internalize modified lipoproteins without normal LDL-receptor feedback.
Foam cells & efflux
Cholesterol-loaded macrophages become foam cells. ApoA-I/HDL-related efflux and effective clearance can oppose accumulation but may be insufficient.
Failed efferocytosis
Ineffective clearance of dying cells permits secondary necrosis, lipid release, and expansion of the necrotic core.
Smooth-muscle migration
Smooth-muscle cells and extracellular matrix build a fibrous structure around the lesion.
Fibrous cap balance
Matrix production can stabilize the cap, while inflammation and proteolysis can weaken it. Calcification has context-dependent patterns.
Instability or erosion
A thin or inflamed cap may rupture; an endothelial surface may also erode without classic rupture, exposing thrombogenic material.
Platelets + thrombin + fibrin
Platelet activation and coagulation rapidly amplify one another at the disrupted surface, forming an arterial clot.
Coronary obstruction
Loss of coronary flow causes myocardial ischemia and can cause myocardial infarction, arrhythmia, pump failure, or sudden death.
Cerebral obstruction
Local thrombosis or embolized material can obstruct a cerebral artery and cause ischemic stroke.
Endogenous clot control
Antithrombin, protein C pathways, and fibrinolysis constrain and later remove clot, but may not restore flow in time.
CONNECTED MODIFIERS
What changes the
pathway’s pressure.
Modifiers affect different stages and timescales. Association does not mean that every modifier independently causes a clinical event.
ApoB, LDL, remnants & Lp(a)
More circulating atherogenic particles over longer time raises the opportunity for entry and retention. LDL-C and ApoB can be discordant.
Diabetes & insulin resistance
Higher VLDL/remnant traffic, glycation, inflammation, endothelial dysfunction, and blood-pressure effects can converge on the artery wall. Insulin itself is not drawn as a single plaque-causing switch.
Open insulin subsystem →Mechanical and endothelial stress
Hypertension and disturbed flow influence endothelial biology, arterial remodeling, and event risk.
Injury and thrombosis context
Tobacco exposure and chronic inflammatory conditions can amplify endothelial, immune, platelet, and coagulation pathways.
Fewer particles reach the wall
Statins, ezetimibe, and PCSK9-targeting therapies lower circulating LDL exposure through distinct mechanisms. Study-specific absolute event differences depend on baseline risk and follow-up.
Open outcome table →Different target, different tradeoff
Antiplatelets and anticoagulants act on clot pathways rather than removing plaque. Bleeding risk and indication are central to their use.
Primary framework: European Atherosclerosis Society LDL consensus ↗ · Response-to-retention model ↗ · 2025 ACS guideline ↗
Educational use only. Sudden chest discomfort, severe shortness of breath, fainting, or new neurologic symptoms require urgent professional assessment; do not use this map to exclude an emergency.